Gilead Sciences Q3 EPS Forecast Decreased by Zacks Research

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Zacks Research lowered their Q3 2026 earnings estimates for shares of Gilead Sciences in a research report issued to clients and investors on Tuesday, April 14th. Zacks Research analyst Team now forecasts that the biopharmaceutical company will earn $2.25 per share for the quarter, down from their previous forecast of $2.30. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share.

GILD has been the subject of several other reports. Royal Bank Of Canada boosted their price target on Gilead Sciences from $118.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Tuesday, April 7th. Wells Fargo & Company raised their price objective on Gilead Sciences from $150.00 to $165.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Scotiabank lifted their target price on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, February 11th. Wolfe Research upped their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the stock an “outperform” rating in a report on Thursday, February 12th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Gilead Sciences from $135.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. Twenty-four investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $156.77.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock opened at $139.77 on Wednesday. The stock has a market capitalization of $173.49 billion, a P/E ratio of 20.65, a PEG ratio of 1.87 and a beta of 0.39. The business has a 50 day simple moving average of $144.86 and a two-hundred day simple moving average of $131.05. Gilead Sciences has a 12 month low of $93.37 and a 12 month high of $157.29. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period in the previous year, the firm posted $1.90 EPS. Gilead Sciences’s revenue was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS.

Hedge Funds Weigh In On Gilead Sciences

Institutional investors have recently bought and sold shares of the company. Nations Financial Group Inc. IA ADV boosted its holdings in Gilead Sciences by 2.4% in the 1st quarter. Nations Financial Group Inc. IA ADV now owns 6,828 shares of the biopharmaceutical company’s stock valued at $952,000 after purchasing an additional 158 shares during the last quarter. J. Derek Lewis & Associates Inc. acquired a new stake in shares of Gilead Sciences during the 4th quarter worth approximately $346,000. Rockefeller Capital Management L.P. increased its holdings in shares of Gilead Sciences by 34.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 88,893 shares of the biopharmaceutical company’s stock worth $10,911,000 after buying an additional 22,559 shares during the last quarter. World Investment Advisors raised its position in shares of Gilead Sciences by 12.7% during the 4th quarter. World Investment Advisors now owns 31,753 shares of the biopharmaceutical company’s stock valued at $3,897,000 after buying an additional 3,589 shares during the period. Finally, Meadowbrook Advisors Group LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $302,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, March 16th. The stock was sold at an average price of $144.23, for a total value of $432,690.00. Following the completion of the sale, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. This trade represents a 1.65% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Friday, February 27th. The stock was sold at an average price of $144.79, for a total value of $1,447,900.00. Following the transaction, the chief executive officer owned 642,308 shares in the company, valued at approximately $92,999,775.32. This represents a 1.53% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 293,280 shares of company stock valued at $42,074,690 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Monday, March 30th. Shareholders of record on Friday, March 13th were paid a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a yield of 2.3%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date of this dividend was Friday, March 13th. Gilead Sciences’s dividend payout ratio is presently 48.45%.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Large public-health deals boost revenue visibility and long-term demand: PEPFAR, The Global Fund and the U.S. State Department expanded commitments for Gilead’s twice-yearly injectable HIV prevention drug lenacapavir, adding capacity to reach up to an additional 1 million people (raising total commitments to ~3 million through 2028). This supports recurring demand and institutional revenue streams for Gilead. PEPFAR and The Global Fund Make Additional Investment in Gilead’s Lenacapavir US-Led Partnership To Provide 1 Mln Lenacapavir
• Positive Sentiment: Analyst optimism: A Citigroup analyst publicly expects GILD shares to rise, which can support near-term buying interest and re-rate sentiment among investors. Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Citigroup Analyst Says
• Neutral Sentiment: Stock movement context: Recent coverage noted that Gilead gained intraday but lagged broader market gains, reflecting mixed sentiment despite company-specific positives. This explains some muted upside versus peers. Here’s Why Gilead Sciences (GILD) Gained But Lagged the Market Today
• Neutral Sentiment: Macro/earnings-signal coverage: Screening tools and notes on earnings momentum include Gilead among medical names to watch ahead of results, which can drive short-term trading flows but not immediate fundamental change. Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
• Negative Sentiment: Small analyst downward revision: Zacks lowered its Q3 FY2026 EPS estimate modestly (from $2.30 to $2.25), signaling slight near-term earnings pressure or conservatism in modeling; investors may view this as a heads-up on quarter-to-quarter variability.
• Negative Sentiment: Reputational and pricing pressure: Activist group AHF publicly protested Gilead over alleged high AIDS drug pricing, a reputational risk that can attract regulatory/political scrutiny and pressure pricing in sensitive markets. Protests: AHF Blasts Gilead Over Extortionate AIDS Drug Pricing
• Negative Sentiment: Competitive pressure in oncology: Peer Bristol Myers’ CAR-T (Breyanzi) is scaling rapidly, which tightens competition in cell therapy markets where Gilead also competes (affecting long-term franchise dynamics). Will Breyanzi’s Strong Uptake Help BMY Offset Generic Competition?

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.